April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.
We present a selection of interesting neurology articles for the month of April in the following slides. See the slide legends for links to the article summaries.
Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Abstract link. **** A Phase 3 Trial of IV Immunoglobulin for Alzheimer Disease. Abstract link.
Sex Dependent Effects of Mild Brain Blast Injury on Neuroendocrine Stress Response. Abstract link. ****Diverging White Matter Trajectories in Children After Traumatic Brain Injury. Abstract link.
FDA Allows Marketing of First Direct-to-Consumer Tests that Provide Genetic Risk Information for Certain Conditions. FDA release.****FDA Approves New Drug to Treat Multiple Sclerosis. FDA release.
FDA Approves XadagoÂ® (Safinamide) for Parkinson’s Disease (PD) Patients. Press release. LB18 ****FDA Approves Expanded Indication for QudexyÂ® XR (topiramate) Extended-Release Capsules to Include Prophylaxis of Migraine Headache in Adults and Adolescents. Press release.
Copeptin for Risk Stratification in Non-Traumatic Headache in the Emergency Setting: a Prospective Multicenter Observational Cohort Study. Abstract link. ****Body Composition Status and the Risk of Migraine. Abstract link.
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. Abstract link. ****Evidence for a Causal Relationship between Low Vitamin D, High BMI, and Pediatric-Onset MS. Abstract link.
Probable REM Sleep Behavior Disorder and Risk of Stroke. Abstract link. Presentation LB1***Integrity of Normal-Appearing White Matter and Functional Outcomes After Acute Ischemic Stroke. Abstract link.